GLP-1 Basal-Bolus Dosing for Stable Therapy and Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional GLP-1 agonist therapies administered as fixed weekly doses may not provide optimal results for all patients, leading to variable efficacy and common gastrointestinal side effects, impacting patient tolerance and adherence.
Innovation Solution
A programmable drug delivery system with a reservoir, pump, controller, and user interface that allows for adjustable basal and bolus dosing of GLP-1 agonists, tailored to patient-specific parameters and real-time glucose readings, enabling flexible and personalized administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fixed weekly doses of GLP-1 agonist are administered, then patient convenience and adherence are improved, but therapeutic efficacy becomes variable and gastrointestinal side effects increase
Solution Approach 1:
The fixed weekly dose is segmented into multiple smaller doses administered throughout the week (daily, twice-weekly, or three-times-weekly dosing regimens). This segmentation maintains patient convenience while improving therapeutic efficacy consistency by providing more frequent, smaller amounts of the medication rather than one large dose, thereby reducing gastrointestinal side effects and maintaining stable drug levels.
2Device complexity
If fixed weekly doses of GLP-1 agonist are administered, then dosing simplicity is improved, but gastrointestinal side effects and impact on patient tolerance increase
Solution Approach 1:
The dosing parameters are changed from a single large weekly dose to multiple smaller doses administered at different frequencies (daily, twice-weekly, or three-times-weekly). This parameter change reduces the peak concentration of the drug in the body, thereby minimizing gastrointestinal side effects while maintaining overall therapeutic efficacy and improving patient tolerance.
3Adaptability or versatility
If fixed weekly doses of GLP-1 agonist are administered, then treatment standardization is improved, but ability to address variable patient needs throughout the dosing period is reduced
Solution Approach 1:
The dosing regimen transitions from a static fixed weekly dose to a dynamic multi-dose schedule that can be adjusted based on patient needs. The system allows for flexible dosing frequencies (daily, twice-weekly, or three-times-weekly) and enables healthcare providers to tailor the regimen to individual patient requirements, thereby improving both adaptability and therapeutic efficacy consistency throughout the dosing period.
Data Source
AI summary
A drug delivery system for administering a GLP-1 agonist therapy includes a reservoir configured to contain a GLP-1 agonist, a pump in fluid communication with the reservoir and configured to deliver the GLP-1 agonist, a controller operatively coupled to the pump, and a user interface operatively coupled to the controller. The controller is programmed to deliver a basal dose of the GLP-1 agonist continuously over a 24-hour period and deliver at least one bolus dose of the GLP-1 agonist in addition to the basal dose. The system allows for independent adjustment of basal and bolus doses based on patient-specific parameters, enabling personalized GLP-1 agonist therapy administration.